In human and mouse lymphocytes the protein tyrosine phosphatase CD45, a key molecule involved in T cell activation, non-covalently associates with the tyrosine kinase p56 lck and lymphocyte phosphatase-associated phosphoprotein (LPAP), a 32 kDa phosphoprotein of unknown function. In order to gain insight into the function of LPAP we have generated an LPAP-deficient Jurkat variant by means of antisense strategies. Analysis of the CD45-p56 lck molecular complex in this cell line revealed that loss of LPAP does not alter the expression or the enzymatic activity of CD45 or p56 lck . In addition, the association between CD45 and p56 lck is not affected in LPAP-deficient T cells. These data suggest that LPAP does not regulate the enzymatic activity of CD45 or p56 lck and is not required for the association between these two proteins. In order to identify polypeptides that preferentially associate with LPAP we established a Jurkat variant expressing a chimeric receptor which was composed of the extracellular portion of the human HLA-A2.1 molecule and the full-length LPAP protein. Comparative two-dimensional analysis of CD45 and HLA-A2 immunoprecipitates obtained from these cells following metabolic labeling resulted in the identification of a 43 kDa protein that preferentially associates with LPAP under mild detergent conditions.
Introduction
The CD45 family of glycoproteins comprises a group of type I transmembrane proteins which are exclusively expressed on nucleated cells of hematopoietic origin. Individual members of the CD45 family consist of variably sized extracellular domains of 400-550 amino acids, a 22 amino acid long transmembrane segment and a highly conserved tandemly repeated intracellular domain of~600 amino acids (reviewed in 1). The variability of the extracellular domains results from differential splicing of at least three exons designated A, B and C, whose differential expression gives rise to CD45RA, RB, RC and RO molecules which are expressed in a cell lineage-specific manner on all leukocytes (2) (3) (4) .
The intracellular domains of all CD45 molecules have intrinsic tyrosine phosphatase activity (5) (6) (7) (8) . The high conservation of the phosphatase domain among different Correspondence to: B. Schraven Transmitting editor: T. Hünig Received 17 September 1997, accepted 24 October 1997 species suggests a crucial role for CD45 in lymphocyte activation and differentiation. Accordingly, it was first demonstrated that CD45-deficient mouse T cell clones fail to proliferate or to produce cytokines in response to antigen or mAb-mediated stimulation of the TCR complex (9, 10) . More recent studies in CD45-deficient mouse and human T cell lines confirmed these initial observations by showing that the signaling capacity of triggering receptors expressed on T and B lymphocytes is strongly impaired in the absence of CD45 (10) (11) (12) (13) (14) . For example, in CD45-deficient T lymphocytes stimulation of the TCR or the CD2 molecule fails to result in tyrosine phosphorylation events, in the generation of phosphatidylinositol-derived second messengers or the appearance of distal markers of T cell activation (12, 13) . Reexpression of the CD45 phosphatase domain overcomes this signaling defect, indicating that it is the enzymatic activity of CD45 that is required to couple surface receptors to the protein tyrosine kinase pathway (15) (16) (17) . Possible candidates for physiologic substrates of CD45 in T lymphocytes are two members of the src family of protein tyrosine kinases, i.e. p56 lck and p59 fyn . Expression of both kinases seems to be essential for optimal T lymphocyte activation and development (18) (19) (20) (21) . Indeed, co-immunoprecipitation as well as co-localization studies revealed that a portion of CD45 associates with p56 lck and to a lesser extent with p59 fyn (22) (23) (24) (25) . Both protein tyrosine kinases carry a negative regulatory tyrosine residue at their C-terminus. Dephosphorylation of these residues enhances enzymatic activity, whereas phosphorylation has an opposite effect (reviewed in 26, 27) . CD45 has been shown to be capable of dephosphorylating both the regulatory Tyr505 of p56 lck as well as Tyr531 of p59 fyn in vitro (24, 28, 29) . More direct evidence for a physiological interaction between CD45 and p56 lck and p59 fyn was provided by biochemical studies of CD45-deficient T lymphoma cell lines where the enzymatic activity of p56 lck and to a lesser extent p59 fyn was found to be reduced due to hyperphosphorylation of the negative regulatory tyrosine residues (28, (30) (31) (32) (33) .
One major question that arises from the physical and functional association between CD45 and p56 lck is whether both molecules associate directly or whether the association is mediated via an adaptor molecule. The elucidation of this question became even more important with the identification of a 32 kDa phosphoprotein that represents a component of a trimolecular complex in human T lymphocytes which consists of pp32, CD45 and p56 lck (22, 23) . The cDNA coding for pp32 has recently been cloned and the human molecule was termed lymphocyte phosphatase-associated phosphoprotein (LPAP), describing its ability to interact with CD45 and its exclusive expression in lymphocytes (34) .
We have previously shown that expression of CD45 is required to stabilize LPAP in human and mouse T cell lines (34) . Moreover, we have demonstrated that the association between LPAP and CD45 is mediated via the transmembrane regions of both molecules (35) . The same is true for the homologous mouse proteins (36, 37) . One attractive model to explain the association between CD45 and p56 lck , therefore, is that LPAP binds to CD45 via its transmembrane portion and recruits p56 lck to CD45 via its intracellular domain.
To test this model we have generated a Jurkat T cell variant in which LPAP mRNA expression was suppressed following transfection with an LPAP antisense construct. Biochemical analysis of the phosphatase activity of CD45 as well as the composition of the CD45-p56 lck complex in the absence of LPAP suggests that LPAP neither regulates the enzymatic activity of CD45 and p56 lck nor is it required for the molecular interaction between both molecules. In order to identify proteins that might associate with LPAP in T cells we established a Jurkat variant expressing a chimeric HLA-A2.1-LPAP molecule. Comparative analysis of CD45 and HLA-A2 immunoprecipitates prepared from this cell line revealed that LPAP preferentially associates with a 43 kDa polypeptide.
Methods

Cells
Wild-type Jurkat cells were cultured in RPMI 1640 (Gibco, Eggenstein, Germany), supplemented with 10% FCS (Gibco), 2% glutamine (Gibco) and 1% penicillinstreptomycin (Gibco). The LPAP antisense transfectants and clone Pete 2.1 were cultured in the same media supplemented with 2 mg/ml G418 (Gibco), whereas the Jurkat cells transfected with the HLA-LPAP chimera were grown in the above media supplemented with 0.3 mg/ml hygromycine. Clone 14 (expressing an LPAP variant that carries a point mutation in the cytoplasmic domain of LPAP resulting in a STOP codon 36 amino acids upstream of the original Cterminus of LPAP) was kindly donated by Dr Sheldon Ratnofsky (BASF Bioresearch, Worchester, MA).
mAb and antisera
The following mAb or polyclonal antisera were used in the experiments. Anti-CD45, AICD45.2, IgG1; anti-HLA-A2, BB7.2, IgG2a; anti-CD3, OKT 3, IgG2a (Ortho, Neckargemü nd, Germany); anti-HLA class I, W6/32, IgG2a; anti-p56 lck (a gift of Dr A. Veillette, McGill Cancer Institute, Montreal, Canada); anti-LPAP (directed at amino acids 175-195 of human LPAP) and anti-MAP kinase (UBI, Lake Placid, NY). For coupling to CNBractivated Sepharose, Protein-A purified AICD45.2 and BB7.2 mAb were used at concentrations of 6 mg/ml. For immunoprecipitations in 96-well plates AICD45.2 was used at 10 µg/ml. The polyclonal antiserum directed at p56 lck was used at a concentration of 1:1000 v/v for immunoprecipitation and Western blot analysis. The LPAP antiserum was diluted 1:10.000 v/v prior to use in Western blotting experiments, whereas the MAP kinase antibody was used at a concentration of 1 µg/ml for Western blotting.
cDNA constructs
The LPAP antisense construct was generated by cloning a full-length LPAP cDNA fragment (34) into the BamHI site of the pNTS1-Neo vector (38) in antisense orientation with respect to the CMV promoter and the HLA-A2.1 construct Pete 2.1 by cloning a full-length cDNA of this HLA allele (39) into the BstXI site of the pEF-BOS expression vector (40) . The chimeric HLA-A2.1-LPAP construct was produced by separately amplifying the extracellular domain of the HLA cDNA with an HLA-2.1-specific forward (ATGGCCGTCATGGCGCCCCG) and a chimeric reverse primer (GGTGACAGAGCTGGACCATCT-CAGGGTGAGGGGC) and the LPAP fragment with an overlapping chimeric forward primer (GCCCCTCACCCTGA-GATGGTCGGGTGGCAGCGCG) and an LPAP-specific reverse primer (GTGACAGGGATGGGACACCAA). The two resulting fragments were used together in a PCR reaction with the HLA-A2.1-specific forward primer and the LPAPspecific reverse primer to generate the chimeric cDNA which was then cloned into the BstXI site of the pEF-BOS vector.
Transfection experiments
Exponentially growing Jurkat cells (2ϫ10 7 ) were used for each transfection. Prior to electroporation cells were pelleted by centrifugation, the culture supernatant was removed and mixed with fresh culture medium at a 1:2 v/v dilution (adapted medium). Cells were washed twice in PBS (Seromed) and resuspended in 300 µl of PBS in an electroporation cuvette (width 4 mm; BioRad, Eggenstein, Germany). cDNA (20 µg) construct in TE buffer was used for transfection of the cells with the antisense LPAP construct, whereas 10 µg of the HLA-A2.1-LPAP and the HLA-A2.1 construct was used in combination with 1 µg of vector carrying the hygromycin (HLA-A2.1-LPAP) or the G418 (HLA-A2.1) resistance gene. The various constructs were mixed with the cell suspension and allowed to incubate for 10 min at room temperature. Electroporation was performed in a BioRad Gene Pulser at 250 V and 960 µF. Following transfection, 450 µl adapted medium was added and cells were again incubated for 10 min at room temperature. Subsequently the cellular debris was carefully removed and transfected cells incubated overnight in 25 ml of adapted medium. After 18 h cells were counted and seeded in 24-well plates at a concentration of 1ϫ10 4 cells/well in fresh medium. Antibiotics diluted in adapted medium were added 24 h later.
Other methods
In vitro kinase assays, in vitro phosphatase assays in 96-well microtiter plates, immunoprecipitation experiments employing mAb coupled to CNBr-Sepharose, analysis of immunoprecipitates by Western blotting, Northern blot analysis, FACS analysis, metabolic labeling and two-dimensional gel electrophoresis were essentially performed as previously described (22, 34, 41, 42) . For immunoprecipitation and Western blotting cells were lysed in a buffer which consisted of 150 mM NaCl, 20 mM Tris-HCl, 10 mM NaF, 1 mM sodium orthovanadate (Merck, Darmstadt, Germany), 1 mM phenylmethylsulfonyl fluoride (Sigma, Munich, Germany), 1 mg/ml aprotinin (Sigma), 1 mg/ml leupeptin (Sigma) and 1% detergent. Detergents that were used in the various experiments were: Triton X-100 (Sigma), digitonin (Sigma) and Brij 58 (Pierce, Oud-Beijerland, The Netherlands). All detergents were kept as 10% stock solutions in distilled water. The digitonin stock solution was prepared as previously described (22) .
Results
Generation and characterization of LPAP-deficient Jurkat variants
In order to analyze the role of LPAP in the assembly of the CD45-p56 lck complex we generated a Jurkat variant that lacks expression of LPAP by means of antisense strategies. To this end wild-type Jurkat cells were electroporated with a construct carrying a full-length LPAP cDNA in anti-sense orientation with respect to the promoter. Transfected cells were grown in media containing G418 and the resistant clones were analyzed for expression of LPAP employing indirect immunofluorescence. As LPAP possesses only a 10 amino acid long extracellular domain (34, 35) our antiserum directed at the N-terminal end of LPAP (34) was unable to detect LPAP expression in intact Jurkat cells. However, the intracellular portion of LPAP was detectable when the cells where permeabilized before addition of a polyclonal LPAP rabbit antibody that is directed at a C-terminal peptide of LPAP (not shown). As a negative control we used a Jurkat variant (clone 14) that expresses a mutant LPAP molecule which carries a single point mutation in the cytoplasmic domain. This point mutation generates a new stop codon 36 amino acids upstream of the original C-terminus of LPAP. Therefore, the mutant protein is not detected by this antiserum (not shown).
Among~50 growing colonies that were analyzed, one cell line (KW46-1D3) produced a double peak in indirect immunofluorescence which indicated that it consisted of two distinct subpopulations of cells, one of which expressed reduced levels of LPAP protein. This cell line was subcloned and the growing single cell colonies re-analyzed for expression of LPAP by anti-LPAP Western blotting (Fig. 1A, left  panel) . Several clones were obtained showing strongly reduced levels of LPAP expression compared to wild-type Jurkat cells (Fig. 1A, right panel) . In contrast, expression of MAP kinase was not affected in the LPAP-deficient clones as judged from parallel analysis of the blot employing a MAP kinase-specific mAb.
To further assess whether the loss of LPAP in the LPAPdeficient clones resulted from reduced levels of LPAP mRNA and not from alterations of the LPAP protein we performed Northern blot analysis employing a radiolabeled full-length LPAP cDNA as a probe. Figure 1 (B) demonstrates that LPAP mRNA is not detectable in LPAP-deficient KW46-1D3-01 and KW46-1D3-16.1 cells, whereas mRNA coding for GAPDH is well expressed. Thus, the loss of detectable LPAP protein in LPAP-deficient Jurkat clones resulted from impaired LPAP mRNA expression and not from alterations of the protein. These data collectively demonstrate that LPAP mRNA was successfully suppressed in these clones.
Loss of LPAP does not influence the expression or enzymatic activity of CD45 Figure 2 shows the expression of CD45 and HLA class I molecules on wild-type Jurkat cells, two LPAP-positive subclones of KW46-1D3 (KW46-1D3-12 and KW46-1D3-22) and two representative LPAP-deficient clones (KW46-1D3-01 and KW46-1D3-16.1). All four cell lines express CD45 on their surface, which further corroborates our previous finding that expression of CD45 does not depend on co-expression of LPAP (34) . Morphologically LPAP-deficient cells were smaller and grew slower than their positive counterparts (not shown).
The finding that the LPAP-deficient clones carry CD45 on their cell surface allowed us to study the role of LPAP in the assembly and regulation of the CD45-p56 lck complex. Since it was possible that LPAP serves to regulate CD45 enzymatic activity, e.g. via dimerization of the CD45 molecules (15,43), we first determined whether the tyrosine phosphatase activity of CD45 was altered in the LPAP-deficient clones. To this end CD45 immunoprecipitates were prepared from Triton X-100 lysates from LPAP-deficient KW46-1D3-01 and KW46-1D3-16.1 cells and subjected to an in vitro phosphatase assay employing p-nitro-phenylphosphate (pNPP) as synthetic substrate (42) . As a control we used the LPAP-positive clone KW46-1D3-12 because this clone expressed similar numbers of CD45 molecules as the LPAP-deficient cells (compare Fig. 2 ). As shown in Fig. 3 , loss of LPAP had virtually no influence on the enzymatic activity of CD45 in the two LPAPdeficient cell lines. Independent of the concentration of dithiothreitol that was used to activate CD45 in vitro, the enzymatic activity of CD45 obtained from LPAP-positive cells was almost the same as the enzymatic activity of CD45 that was precipitated from the two LPAP-deficient cell lines. These data strongly suggest that expression of LPAP does not influence the enzymatic activity of CD45.
Loss of LPAP does not alter the association between CD45 and p56 lck , and does not influence the enzymatic activity of p56 lck We next determined whether loss of LPAP would have any influence on the association between CD45 and p56 lck (22, 23, 25, 34, 44) . To this end we compared CD45 immunoprecipitates obtained from LPAP-positive and LPAP-deficient cells for co-immunoprecipitation of p56 lck . As previously reported, CD45 immunoprecipitates prepared from Triton X-100 lysates of the two cell lines that were investigated did not contain detectable levels of p56 lck (22) . In contrast, when CD45 immunoprecipitates were prepared from Digitonin or Brij 58 lysates, p56 lck was readily detectable in Western blot analysis (Fig. 4A) . However, no difference in the relative amounts of p56 lck that were co-precipitated by CD45 mAb were observed among the LPAP-positive and the LPAPdeficient cell lines. This suggests that loss of LPAP expression has no influence on the ability of CD45 to interact with p56 lck .
We next addressed the question whether lack of LPAP would have any influence on the tyrosine kinase activity of p56 lck . Figure 4 (B) demonstrates that the enzymatic activity of p56 lck in LPAP-deficient cell lines is identical to wild-type Jurkat cells as judged from an in vitro kinase assay where autophosphorylation of p56 lck was determined.
Generation and characterization of Jurkat variants expressing chimeric HLA-A2.1-LPAP molecules
Although the data shown in Figs 1-4 demonstrated that LPAP is apparently not involved in the regulation or the assembly of the CD45-p56 lck complex, we could not rule out the possibility that LPAP modulates TCR-CD3-mediated signal transduction in T lymphocytes by a mechanism that does not involve CD45 or p56 lck . To further address this question we established a Jurkat variant expressing a chimeric LPAP molecule which is accessible from the extracellular side by mAb and thus allows co-cross-linking of LPAP with the TCR-CD3 complex. To this end a cDNA coding for the extracellular portion of the human HLA-A2.1 molecule (which is normally not expressed by Jurkat cells) was fused to a full-length LPAP cDNA (containing the extracellular portion, the transmembrane region as well as the entire intracytoplasmic tail of LPAP) giving rise to a HLA-A2.1-LPAP chimera. This chimera or, as a control, a full-length HLA-A2.1 molecule was transfected into wild-type Jurkat cells and growing colonies were analyzed by means of indirect immunofluorescence and anti-LPAP Western-blotting for expression of HLA-A2.1 molecules and HLA-A2.1-LPAP chimeras. Figure 5 (A) depicts LPAP expression of several hygromycin-resistant clones transfected with the HLA-A2.1-LPAP chimera (CB clones) as well as one clone that expresses a full-length HLA-A2.1 construct (Pete 2.1). Among the various CB clones, three clones express the 65 kDa HLA-A2.1-LPAP chimera. Interestingly, the levels of expression of the chimera inversely correlate with the amounts of endogenous wild-type LPAP molecules that are detectable. Thus, in clone CBC1 which expresses the lowest levels of the chimera, LPAP expression is only slightly reduced, whereas much lower amounts of endogenous LPAP are detectable in clone CB2 and almost no wild-type protein is detectable in clone CB4 which expresses the highest amounts of the chimera. In contrast, even high level expression of the HLA-A2.1 construct (clone Pete 2.1) does not have any influence on the expression of endogenous LPAP.
We used clones Pete 2.1 and clone CB4 for functional studies of the LPAP molecule. We first analyzed whether cocross-linking of the chimera with the CD3 complex would have any influence on the level of receptor-mediated tyrosine phosphorylation of intracellular molecules or rise in intracellular calcium. No obvious differences were observed between wild-type Jurkat cells, the CB4 variant and clone Pete 2.1 (not shown). Similarly, mAb mediated co-crosslinking of the transfected molecules to the TCR-CD3 complex did not alter induction of NF-AT activity as judged from experiments where the individual Jurkat variants were transiently transfected with a luciferase reporter gene construct that is driven by the transcription factor NF-AT. Similar results were obtained with a reporter construct that is regulated by the full-length IL-2 promoter (not shown). These data collectively indicate that LPAP is also not involved in the protein tyrosine kinase pathway and in TCR-CD3-mediated activation of the IL-2 gene.
Analysis of the CD45-LPAP complex by means of twodimensional gel electrophoresis
It has previously been suggested that LPAP expresses a WW domain in its intracellular portion which could mediate interactions with other proteins (36) . Since the data that we had obtained with the LPAP-deficient cell lines did not support the idea that LPAP is required for the interaction between CD45 and p56 lck , we were interested to identify proteins that specifically associate with CD45 or LPAP in Jurkat cells. The availability of the CB4 and the Pete 2.1 cells allowed us to investigate this question without using our polyclonal LPAP antisera that are directed at intracellular portions of LPAP and possibly interfere with the binding of proteins to the intracytoplasmic domain of LPAP.
HLA-A2 and CD45 immunoprecipitates were obtained under mild detergent conditions (Brij 58) from CB4 cells or from Pete 2.1 cells metabolically labeled with [ 3 H]leucine and analyzed by means of two-dimensional gel electrophoresis. Figure 6 demonstrates that a CD45 mAb co-precipitated an almost identical pattern of proteins from CB4 and Pete 2.1 cells (Fig. 6A and C) . Perhaps more importantly, the pattern 3) and LPAP-positive KW46-1D3-12 cells (lanes 4-6) for co-precipitation of p56 lck . Cells (3ϫ10 7 ) were lysed in buffer supplemented with 1% Triton X-100 (lanes 1 and 4), 1% digitonin (lanes 2 and 5) and 1% Brij 58 (lanes 3 and 6). Post-nuclear lysates were subjected to CD45 immunoprecipitation and analyzed for co-precipitation of p56 lck by means of Western blotting (upper panel). Subsequently the blot was incubated with LPAP-specific antisera to demonstrate the differences in the amounts of LPAP that are co-precipitated by CD45 mAb in LPAP-deficient and LPAP-positive cells (lower panel). 10% of the individual immunoprecipitates were subjected to in vitro phosphatase assay as described for Fig. 3. (B) p56 lck immunoprecipitates were prepared from Triton X-100 lysates corresponding to 1ϫ10 7 of proteins that were co-precipitated by the HLA-A2-specific antibody from CB4 cells was also very similar to the CD45 immunoprecipitates although the HLA-A2 mAb precipitated much higher amounts of the HLA-A2.1-LPAP chimera from the CB4 cells than the CD45 mAb ( Fig. 6A and B) . Moreover, the CD45 and the HLA-A2 immunoprecipitates clearly differed in two proteins, i.e. a 56 kDa protein with an isoelectric point of 5.6 that preferentially co-precipitated with CD45 (open arrowheads) in both CB4 and Pete 2.1 cells, and a more basic 43 kDa polypeptide that was preferentially precipitated by the HLA-A2 antibody from CB4 cells (open arrowheads).
Discussion
LPAP represents a 32 kDa phosphoprotein that associates with the protein tyrosine phosphatase CD45 in human and mouse lymphocytes (22, 23, 34, 35, 43, 45) . Since LPAP was originally identified as a component of a trimolecular complex which is composed of CD45, p56 lck and LPAP (22, 23, 25, 34, 44) , it was proposed that LPAP could serve as an adaptor protein which brings p56 lck into proximity of CD45 and thus allows the phosphatase to dephosphorylate the negative regulatory tyrosine residue of p56 lck . This idea was further supported by the finding that LPAP serves as a common substrate for p56 lck and CD45 in vivo under particular experimental conditions (22, 34) . The analysis whether LPAP indeed serves an adaptor function in T lymphocytes required T cells that lack expression of LPAP but express p56 lck and CD45. We here describe the generation and biochemical characterization of LPAP-deficient Jurkat T cells.
Transfection of wild-type Jurkat cells with a full-length LPAP cDNA construct in antisense orientation resulted in generation of an LPAP-deficient Jurkat variant which still expresses MAP kinase ( Fig. 1), p56 lck (Fig. 4) and CD45 (Fig. 2) . The latter finding corroborates our previous finding that CD45 expression does not depend on LPAP expression, whereas the opposite is clearly the case (34) .
Comparative biochemical analysis of LPAP-positive and LPAP-deficient clones revealed that loss of LPAP does not alter the enzymatic activity of CD45 (Fig. 3) . Thus, LPAP apparently is not a physiological regulator of CD45. Moreover, the association between p56 lck and CD45 was also found not to be affected in CD45-LPAP-deficient cells indicating that LPAP does not serve as an adaptor protein that mediates the association between CD45 and p56 lck (Fig. 4) . Consistent with this conclusion we also did not observe any alterations of the enzymatic activity of p56 lck in LPAP-deficient cell lines (Fig. 4) . Collectively these data suggest that LPAP is not involved in the assembly and regulation of the CD45-p56 lck complex.
Unfortunately we could not analyze receptor-mediated signal transduction in our LPAP-deficient cells because these cells did no longer express a TCR-CD3 complex or CD2 molecules on their surface (not shown). We do not believe that this particular phenotype is caused by the loss of LPAP but rather is due to a microheterogeneity within the parental cell population since CD3/CD2-deficient (LPAP-positive) Jurkat clones were also occasionally obtained following limiting dilution cloning of the non-transfected parental cell line. Incidentally these cells showed a similar morphology and growth behavior as the LPAP-negative clones, suggesting that loss of LPAP and altered morphology/growth rate are unrelated events. Moreover, re-expression of LPAP in the LPAP-deficient cells by means of transient transfection did not rescue CD2 or CD3 expression (data not shown), which also demonstrates that loss of LPAP is unrelated to the loss of CD2 and/or CD3.
In order to gain further insight into the function of LPAP we generated Jurkat variants expressing chimeric LPAP molecules which are composed of the extracellular portion of the human HLA-A2.1 molecule and LPAP (CB clones). Interestingly, the level of expression of the chimeras inversely correlated with the expression of wild-type LPAP (Fig. 5 ). Based on our previous studies which indicated that LPAP is stabilized through its interaction with CD45 (34) and that this interaction is mediated via the transmembrane regions of both molecules (35) (36) (37) it seems likely that the chimera and wild-type LPAP compete with each other for binding to the transmembrane portion of CD45 and that those molecules which cannot bind to CD45 are degraded in the cytoplasm.
In a transfectant in which the chimera is expressed in much higher copy numbers than the endogenous protein, like the Jurkat variant CB4, the wild-type protein becomes completely degraded, which results in lack of detection by Western blotting.
Two-dimensional analysis of CD45 and HLA-A2 immunoprecipitates obtained from metabolically labeled CB4 and Pete 2.1 cells (Fig. 6) revealed that CD45 and HLA-A2 immunoprecipitates obtained from CB4 cells are largely identical but differ in two molecules, p43 and p56, which seem to preferentially associate with either CD45 (p56) or LPAP (p43).
Whereas the 56 kDa molecule that associates with CD45 most likely represents the CD45-associated portion of p56 lck [it shares mol. wt and isoelectric point with the protein tyrosine kinase (46) ], the p43 molecule is a good candidate for a novel molecule that specifically binds to the intracytoplasmic portion of LPAP. Consistent with this view, it has previously been suggested that LPAP expresses a WW domain in its intracytoplasmic tail which could mediate binding to other intracellular proteins (36) . The availability of mAb directed at the extracellular portion of the chimeric HLA-A2-LPAP molecule should now allow purification of the p43 molecule and characterization of the protein on the molecular level.
Co-cross-linking of the HLA-A2.1-LPAP chimera on CB4 cells to the TCR-CD3 complex did not influence early and late key events of human T cell activation. Thus, the level of receptor-mediated tyrosine phosphorylation of intracellular proteins, the rise in intracellular calcium and the activation of the transcription factor NF-AT as well as the IL-2 promoter are not altered by cross-linking the chimera to the TCR-CD3 complex. Together with the observation that loss of LPAP does not influence the composition and function of p56 lck and CD45, this indicates that LPAP is likely not involved in the protein tyrosine kinase pathway and the regulation of the IL-2 gene. This view is also supported by previous data obtained in CD45-deficient human and mouse T cell lines (16, 17) . These cell lines are also deficient in LPAP expression because LPAP is not stabilized by the transmembrane region of CD45 (34) . Expression of the CD45 phosphatase domains in these cells rescues the signaling defect but not LPAP expression.
We cannot exclude the possibility that LPAP is involved in a pathway of T cell activation that was not investigated in this study. One approach towards the elucidation of this question is the generation of a LPAP-deficient mouse. Such an animal is also of particular interest because LPAP expression was found to be strikingly reduced in thymocytes from CD45 exon 9 targeted mice which completely lack CD45 expression (J. Stone et al., unpublished data). Thus, to elucidate to what extent the phenotype of the CD45-deficient mouse is influenced by the concomitant loss of LPAP it is required to selectively eliminate the LPAP gene in vivo. 
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lymphocyte phosphatase-associated phosphoprotein pNPP p-nitro-phenylphosphate
